middle.news
How Will Biotron Navigate Funding and Clinical Milestones After Sedarex Acquisition?
7:02pm on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Will Biotron Navigate Funding and Clinical Milestones After Sedarex Acquisition?
7:02pm on Thursday 26th of February, 2026 AEDT
Key Points
Half-year net loss of $920,969 reported
Completed acquisition of Sedarex Limited with global patents for next-gen general anaesthetic
Raised $2.5 million through placements and rights issue to fund acquisition and R&D
Lead HBV drug BIT-HBV001 shows superior antiviral activity to current treatment Tenofovir
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE